Longitudinal SV2A and MRI in Premanifest HD
Longitudinal Imaging of Striatal Synaptic Density and Volume in People With Premanifest Huntington's Disease.
Universitaire Ziekenhuizen KU Leuven
35 participants
Dec 4, 2024
INTERVENTIONAL
Conditions
Summary
AIM: to compare the sensitivity of SV2A PET and volumetric MRI to detect longitudinal striatal changes in premanifest HD. DESIGN: The investigators will include late premanifest HD mutations carriers and matched healthy controls. All subjects will undergo a clinical examination, with comprehensive assessment of motor and non-motor symptoms, and imaging evaluation consisting of 18F-SynVesT-1 PET and volumetric MRI at baseline and after 2 years.
Eligibility
Inclusion Criteria6
- Age 20-75 years inclusive.
- Capacity to understand the informed consent form.
- HD mutation carriers:
- HTT (CAG)n ≥ 40
- HD-ISS < 2
- CAP100 score > 70
Exclusion Criteria7
- neuropsychiatric diseases (other than HD for HD mutation carriers)
- major internal medical diseases
- white matter lesion load on FLAIR Fazekas score 2 or higher or other relevant MRI abnormalities
- history of alcohol abuse or current alcohol abuse (chronic use of more than 15 units per week) or drug abuse
- contraindications for MR
- pregnancy
- previous participation in other research studies involving ionizing radiation with more than 1 mSv in the previous 12 months.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Positron Emission Tomography (PET) of synaptic vesicle protein 2A (SV2A) using the radioligand 18F-SynVesT-1.
Magnetic resonance imaging of brain volume.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06626412